2020 |
04/30 | 375 | 387 | 370 | 387 | +3.75% | 3,554,400 | 276億3446万 | +9.94% |
04/28 | 382 | 389 | 368 | 373 | -2.86% | 3,062,000 | 266億3477万 | +6.88% |
04/27 | 15:00 再生医療製品ステムカイマルの開発費用に対する希少疾病用再生医療等製品試験研究助成金の2019年度交付額確定に関するお知らせ |
04/27 | 378 | 392 | 373 | 384 | +1.05% | 3,953,900 | 274億2024万 | +11.3% |
04/24 | 370 | 392 | 360 | 380 | +3.26% | 6,728,300 | 271億3461万 | +11.11% |
04/23 | 347 | 371 | 345 | 368 | +6.98% | 3,728,800 | 262億7773万 | +8.55% |
04/22 | 338 | 356 | 332 | 344 | -1.15% | 2,165,200 | 245億6397万 | +2.38% |
04/21 | 359 | 363 | 343 | 348 | -2.25% | 2,642,200 | 248億4959万 | +3.88% |
04/20 | 15:00 当社と東京工業大学による共同研究開発計画の関東経済産業局公募事業の2019年度補助金交付額確定に関するお知らせ |
04/20 | 376 | 377 | 354 | 356 | -4.81% | 3,091,200 | 254億2085万 | +7.55% |
04/17 | 380 | 385 | 369 | 374 | -2.09% | 2,947,600 | 267億617万 | +14.37% |
04/16 | 377 | 388 | 368 | 382 | 0% | 3,617,400 | 272億7743万 | +18.63% |
04/15 | 359 | 390 | 354 | 382 | +8.52% | 6,342,100 | 272億7743万 | +20.5% |
04/14 | 348 | 373 | 343 | 352 | +3.53% | 5,733,600 | 251億3522万 | +12.82% |
04/13 | 332 | 342 | 320 | 340 | +1.49% | 2,930,800 | 242億7834万 | +10.03% |
04/10 | 334 | 337 | 326 | 335 | -0.89% | 1,758,000 | 239億2130万 | +8.77% |
04/09 | 348 | 352 | 326 | 338 | -2.31% | 3,714,600 | 241億3552万 | +10.46% |
04/08 | 330 | 357 | 317 | 346 | +9.49% | 5,717,600 | 247億678万 | +13.07% |
04/07 | 15:00 Axion BioSystem社新製品「MAESTRO Z」販売開始に関するお知らせ |
04/07 | 318 | 327 | 311 | 316 | +1.94% | 2,460,300 | 225億6457万 | +3.95% |
04/06 | 308 | 314 | 296 | 310 | +0.98% | 2,277,100 | 221億3613万 | +1.97% |
04/03 | 340 | 344 | 303 | 307 | -9.71% | 4,498,500 | 219億2191万 | +0.99% |
04/02 | 345 | 360 | 336 | 340 | +0.89% | 3,545,400 | 242億7834万 | +11.48% |
04/01 | 371 | 381 | 336 | 337 | -8.17% | 5,499,800 | 240億6412万 | +10.49% |
03/31 | 415 | 434 | 358 | 367 | -7.32% | 14,233,200 | 262億632万 | +19.54% |
03/30 | 15:00 再生医療向け臨床用iPS細胞の作製サービスの開始について |
03/30 | 10:00 新型コロナウイルス用ワクチンの開発を目指す国際的研究コンソーシアムへの参加について |
03/30 | 318 | 396 | 310 | 396 | +25.32% | 14,735,600 | 282億7712万 | +28.99% |
03/27 | 321 | 330 | 307 | 316 | -1.56% | 3,392,400 | 225億6457万 | +3.95% |
03/26 | 348 | 367 | 315 | 321 | +6.64% | 10,060,900 | 229億2161万 | +5.25% |
03/25 | 305 | 310 | 295 | 301 | +1.35% | 1,943,200 | 214億9347万 | -0.99% |
03/24 | 296 | 302 | 290 | 297 | +3.13% | 2,156,400 | 212億784万 | -2.62% |
03/23 | 303 | 303 | 286 | 288 | -5.26% | 2,007,200 | 205億6518万 | -5.26% |
03/19 | 319 | 322 | 292 | 304 | 0% | 2,545,400 | 217億769万 | -0.33% |
03/18 | 311 | 334 | 300 | 304 | -2.88% | 5,977,100 | 217億769万 | -0.65% |
03/17 | 250 | 324 | 250 | 313 | +20.85% | 8,955,600 | 223億5035万 | +2.29% |
03/16 | 15:00 当社と順天堂大学による共同事業のNEDO公募事業の助成期間延長決定および交付増額に関するお知らせ |
03/16 | 254 | 277 | 243 | 259 | +6.58% | 2,544,300 | 184億9438万 | -15.36% |
03/13 | 233 | 253 | 227 | 243 | -3.95% | 3,053,300 | 173億5187万 | -21.36% |
03/12 | 247 | 265 | 245 | 253 | -0.78% | 2,838,100 | 180億6594万 | -18.91% |
03/11 | 274 | 287 | 254 | 255 | -5.56% | 2,033,000 | 182億875万 | -19.05% |
03/10 | 250 | 273 | 238 | 270 | +1.5% | 3,829,600 | 192億7986万 | -15.09% |
03/09 | 295 | 298 | 260 | 266 | -13.07% | 3,258,800 | 189億9423万 | -17.13% |
03/06 | 302 | 317 | 301 | 306 | -0.97% | 1,759,400 | 218億5050万 | -5.56% |
03/05 | 324 | 325 | 305 | 309 | -2.22% | 1,877,400 | 220億6472万 | -5.79% |
03/04 | 302 | 322 | 302 | 316 | +0.96% | 1,525,700 | 225億6457万 | -3.95% |
03/03 | 331 | 333 | 309 | 313 | -0.63% | 2,274,200 | 223億5035万 | -3.99% |
03/02 | 297 | 325 | 296 | 315 | +6.06% | 3,452,300 | 224億9317万 | -2.17% |
02/28 | 317 | 327 | 293 | 297 | -10% | 4,641,200 | 212億784万 | -6.6% |
02/27 | 344 | 362 | 323 | 330 | -5.71% | 6,285,100 | 235億6427万 | +5.1% |
02/26 | 390 | 416 | 346 | 350 | -12.06% | 13,315,200 | 249億9241万 | +13.27% |
02/25 | 10:00 再生医療製品ステムカイマルの第II相臨床試験における第一例目の被験者への投与開始のお知らせ |
02/25 | 372 | 436 | 359 | 398 | +11.8% | 19,465,200 | 284億1994万 | +30.92% |
02/21 | 332 | 359 | 329 | 356 | +8.54% | 4,806,900 | 254億2085万 | +20.27% |
02/20 | 333 | 336 | 321 | 328 | 0% | 2,177,900 | 234億2146万 | +13.1% |
02/19 | 317 | 336 | 310 | 328 | +6.15% | 3,434,400 | 234億2146万 | +15.09% |
02/18 | 310 | 325 | 300 | 309 | -0.96% | 2,689,500 | 220億6472万 | +9.96% |
02/17 | 288 | 314 | 281 | 312 | +8.33% | 3,371,300 | 222億7894万 | +12.64% |
02/14 | 306 | 307 | 283 | 288 | -6.8% | 3,094,400 | 205億6518万 | +5.49% |
02/13 | 15:00 営業外収益・営業外費用及び特別損失の計上に関するお知らせ |
02/13 | 15:00 2020年3月期第3四半期決算短信〔日本基準〕(連結) |
02/13 | 314 | 315 | 306 | 309 | -0.96% | 1,372,500 | 220億6472万 | +14.87% |
02/12 | 309 | 323 | 305 | 312 | +0.32% | 2,108,800 | 222億7894万 | +17.74% |
02/10 | 320 | 320 | 303 | 311 | -3.12% | 2,410,000 | 222億754万 | +19.16% |
02/07 | 341 | 357 | 315 | 321 | -4.75% | 7,793,600 | 229億2161万 | +24.9% |
02/06 | 330 | 367 | 312 | 337 | +5.64% | 11,147,800 | 240億6412万 | +33.2% |
02/05 | 15:00 分担企業として参加するAMED公募事業の2018年度補助金交付額確定に関するお知らせ |
02/05 | 317 | 341 | 311 | 319 | +3.24% | 5,963,700 | 227億7879万 | +28.63% |
02/04 | 331 | 345 | 302 | 309 | -8.31% | 7,550,000 | 220億6472万 | +27.16% |
02/03 | 329 | 382 | 327 | 337 | -1.17% | 11,461,100 | 240億6412万 | +41% |
01/31 | 385 | 393 | 332 | 341 | -3.4% | 12,213,200 | 243億4974万 | +45.73% |
01/30 | 472 | 475 | 343 | 353 | -13.48% | 35,594,500 | 252億663万 | +54.15% |
01/29 | 400 | 408 | 392 | 408 | +24.39% | 5,265,900 | 291億3401万 | +82.14% |
01/28 | 285 | 328 | 281 | 328 | +32.26% | 11,074,400 | 234億2146万 | +51.85% |
01/27 | 214 | 266 | 212 | 248 | +20.39% | 13,654,300 | 177億890万 | +16.98% |
01/24 | 206 | 207 | 204 | 206 | -0.48% | 300,300 | 147億981万 | -2.37% |
01/23 | 209 | 209 | 206 | 207 | -0.96% | 247,700 | 147億8122万 | -1.9% |
01/22 | 209 | 210 | 208 | 209 | 0% | 131,200 | 149億2404万 | -1.42% |
01/21 | 208 | 211 | 208 | 209 | +0.48% | 192,400 | 149億2404万 | -1.88% |
01/20 | 208 | 209 | 206 | 208 | 0% | 175,800 | 148億5263万 | -2.8% |
01/17 | 208 | 209 | 206 | 208 | -0.48% | 199,800 | 148億5263万 | -3.26% |
01/16 | 212 | 212 | 207 | 209 | -0.95% | 235,000 | 149億2404万 | -2.79% |
01/15 | 209 | 212 | 207 | 211 | +0.48% | 276,500 | 150億6685万 | -2.31% |
01/14 | 211 | 212 | 208 | 210 | 0% | 159,400 | 149億9544万 | -2.78% |
01/10 | 210 | 213 | 210 | 210 | 0% | 154,400 | 149億9544万 | -3.23% |
01/09 | 205 | 211 | 205 | 210 | +2.94% | 275,100 | 149億9544万 | -3.67% |
01/08 | 207 | 207 | 202 | 204 | -1.92% | 561,800 | 145億6700万 | -6.85% |
01/07 | 208 | 209 | 207 | 208 | 0% | 155,400 | 148億5263万 | -5.45% |
01/06 | 207 | 209 | 206 | 208 | -1.42% | 277,400 | 148億5263万 | -5.88% |
2019 |
12/30 | 210 | 212 | 207 | 211 | -0.47% | 280,900 | 150億6685万 | -4.95% |
12/27 | 208 | 213 | 208 | 212 | +1.92% | 299,500 | 151億3826万 | -4.93% |
12/26 | 207 | 209 | 207 | 208 | +0.48% | 598,100 | 148億5263万 | -6.73% |
12/25 | 210 | 211 | 207 | 207 | -1.9% | 446,500 | 147億8122万 | -7.59% |
12/24 | 209 | 214 | 209 | 211 | +0.96% | 460,600 | 150億6685万 | -6.22% |
12/23 | 216 | 216 | 207 | 209 | -3.69% | 1,027,900 | 149億2215万 | -7.52% |
12/20 | 217 | 218 | 215 | 217 | 0% | 326,100 | 154億9334万 | -4.41% |
12/19 | 217 | 219 | 217 | 217 | -0.91% | 229,900 | 154億9334万 | -4.41% |
12/18 | 219 | 221 | 217 | 219 | 0% | 249,300 | 156億3613万 | -3.52% |
12/17 | 219 | 220 | 217 | 219 | +0.46% | 258,700 | 156億3613万 | -3.52% |
12/16 | 222 | 223 | 218 | 218 | -2.68% | 354,100 | 155億6474万 | -3.96% |
12/13 | 229 | 229 | 223 | 224 | -2.18% | 390,500 | 159億9312万 | -1.32% |
12/12 | 230 | 231 | 226 | 229 | -0.43% | 298,400 | 163億5240万 | +0.88% |
12/11 | 231 | 233 | 227 | 230 | +0.44% | 264,900 | 164億2381万 | +1.32% |
12/10 | 226 | 231 | 226 | 229 | +1.78% | 400,300 | 163億5240万 | +0.88% |
12/09 | 226 | 226 | 223 | 225 | +0.45% | 103,500 | 160億6677万 | -0.88% |
12/06 | 225 | 226 | 223 | 224 | -0.44% | 140,900 | 159億9536万 | -0.88% |
12/05 | 227 | 228 | 225 | 225 | -0.44% | 154,200 | 160億6677万 | -0.88% |
12/04 | 228 | 228 | 225 | 226 | -0.88% | 228,200 | 161億3818万 | -0.44% |
12/03 | 227 | 230 | 226 | 228 | -0.87% | 193,800 | 162億8099万 | +0.44% |
12/02 | 230 | 232 | 227 | 230 | +0.44% | 334,400 | 164億2381万 | +1.77% |